Slides
Page 1
Q3 2026 Conference Call Note Wacker Chemie AG Dr. Christian Hartel (CEO), Dr. Tobias Ohler (CFO) October 29th, 2026
Page 2
Disclaimer 2 The information contained in this presentation is for background purposes only and is subject to amendment, revision and updating. Certain statements and information contained in this presentation may relate to future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. In addition to statements which are forward-looking by reason of context, including without limitation, statements referring to risk limitations, operational profitability, financial strength, performance targets, profitable growth opportunities, and risk adequate pricing, other words such as "may, will, should, expects, plans, intends, anticipates, believes, estimates, predicts, or continue", "potential, future, or further", and similar expressions identify forward-looking statements. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions which could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These include, among other factors, changing business or other market conditions and the prospects for growth anticipated by the Company's management. These and other factors could adversely affect the outcome and financial effects of the plans and events described herein. Statements contained in this presentation regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. The Company does not undertake any obligation to update or revise any statements contained in this presentation, whether as a result of new information, future events or otherwise. In particular, you should not place undue reliance on forward-looking statements, which speak only as of the date of this presentation. Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 Front page: New Silicone Solution for EV Battery Cooling Systems. ELASTOSIL® LR 3822 offers coolant resistance, automated assembly benefits and long-term sealing performance.
Page 3
Financials EBITDA markedly higher yoy on cost measures. Strong net cash flow with extraordinary effects1. REFOCUS Capital Markets Day 2026 WACKER defined strategic priorities for REFOCUS – the next step in its evolution. A holistic approach that defines how we operate, compete and create value. REFOCUS drives our ambitions for growth, profitability and ROCE. WACKER Q3 2026 highlights Overview 3 Operations PACE cost and efficiency program clearly supports Q3/26 performance, > €300m in savings targeted in 2028. Chemicals Higher volumes in some areas, improved mix and focused pricing to protect margins. 217 €m EBITDA Polysilicon The Section 232 - in its current framework - does not achieve its objective of revitalizing the U.S. polysilicon sector. Q3/24: €154m 1.47 €bn Sales 261€m Net Debt FY25: €886m 476 €m Net Cash Flow incl. €290m extraordinary effects1. Q3/25: €1.34bn Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 Q3/25: €19m Q3/25: €112m 1) Includes €170m from Siltronic-related effects and €120m from changes to funding arrangement to phased retirement obligation
Page 4
REFOCUS is the foundation for our structural financial ambitions 4 GDP+ Focus on mix improvement & Accelerate Growth businesses Financial Ambitions 15% ± 2pp Structural EBITDA margin band Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 >10% ROCE > cost of capital
Page 5
FY 2026 outlook updated EBITDA expected in the upper half of range from €625 to 750m FY 2026 group outlook • Sales: Mid-single-digit percentage higher year over year • Reported EBITDA in the upper half of range from €625 to 750m, incl. approx. €70m in special income (Prior: In the range from €625 to 750m) • Special income: +€37m from capital option effects from pensions in Others in Q2/26 and +€35m from solar contract cancelation in Polysilicon in Q3/26 • Net financial debt lowered to approx. €200m due to extraordinary effects1 in Q3/26 (Prior: Around €500m) • Outlook does not include significant effects from trade policies 5 2026 Outlook Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 1) Includes €170m from Siltronic-related effects and €120m from changes to funding arrangement to phased retirement obligation
Page 6
Q3/26 Op. EBITDA at €182m supported by PACE & Volume/Mix Profit & loss 6 Q3 2026 Q3 2025 Sales 1,466 1,340 Gross profit 238 154 Gross profit % 16.2% 11.5% EBITDA 217 112 EBITDA % 14.8% 8.3% EBIT 103 -20 EBIT % 7.0% -1.5% Net income 87 -82 EPS 1.68 -1.73 Q3 comments • Sales +9% yoy, Price +6%, Volume/Mix +2%, FX +1%, • Operating EBITDA at €182m, +63% yoy on PACE cost and efficiency program (Q3/26 >€60m) and Volume/Mix • Reported EBITDA at €217m includes €35m special income 28 83 15 Sales Q3 2025 Volume/Mix Price FX Sales Q3 2026 1,340 1,466 +9% Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 7
Financials with €2.0bn in liquidity and €4.3bn in equity Balance sheet 7 Balance sheet per 09/30/26 Cash & securities: • High level of liquidity at €2.0bn Accounts receivables: • + €155m higher YTD due to seasonality in Chems Pension liabilities: • - €104m lower at €522m due to the capital option effects and higher discount rates Shareholder equity: • + €569m higher at €4.3bn, equity ratio at 49% 18% 23% 13% 19% 17% 16% 52% 43% 12/31/25 09/30/26 €8.4bn €8.8bn Fixed Assets Inventories Receivables Cash / Securities 15% 14% 28% 26% 12% 11% 45% 49% 12/31/25 09/30/26 €8.4bn €8.8bn Equity Provisions Financial Liabilities Liabilities Assets Liabilities Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 8
Silicones: Pricing, mix, and cost performance drive EBITDA Quarterly figures 86 42 117 123 116 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +35% 16.2% 673 602 708 757 729 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +8% Sales (€m) 16.5% 16.0%6.9%12.8% EBITDA (€m) / margin 8 Q3 Comments FY 2026 Outlook • Sales higher yoy by a mid-single-digit percentage, higher volumes and prices partially offset by negative FX effects • Price increases to offset recent cost inflation • EBITDA margin above prior year on PACE and strong operational performance • Sales higher yoy on pricing, better mix and FX • EBITDA benefited additionally yoy from PACE cost and efficiency program • Order intake with typical seasonality, total order book higher yoy Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 9
Polymers: Cost savings support EBITDA Quarterly figures 9 Q3 Comments FY 2026 Outlook • Sales higher yoy by a mid-single-digit percentage • Dynamic price management vs. volatile raw materials • EBITDA margin above prior year on PACE and strong operational performance 47 34 50 69 75 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +58% 17.0% 344 312 333 406 381 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +11% Sales (€m) 14.9% 19.6%11.0%13.7% EBITDA (€m) / margin • Sales yoy higher as prices follow raw material inflation • EBITDA yoy higher, mainly supported by PACE program and includes effects from raw material volatility • Order intake with typical seasonality, total order book higher yoy Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 10
Biosolutions: Sales improvement yoy Quarterly figures 10 Q3 Comments FY 2026 Outlook • Sales up yoy by a high-single-digit percentage • EBITDA around €30m 8 3 13 7 8 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 €0m 7.4% 93 89 100 99 100 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +8% Sales (€m) 13.5%8.8% 2.8% EBITDA (€m) / margin • BioPharma and Life Science Chemicals developed positively • Focus on commercial excellence to fill capacities 7.9% Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 11
Polysilicon: Strong semi growth and solar uncertainty Quarterly figures 11 Q3 Comments FY 2026 Outlook • Sales up yoy by a high-single-digit percentage • EBITDA close to prior year level • Semi volumes with double-digit growth • Solar stays under pressure, no significant effects from trade policies included in outlook • Semi volume growth continues • EBITDA benefitted from higher semi volumes, good cost performance and special income1 • Section 232 - in its current framework - does not achieve its objective of revitalizing the U.S. polysilicon sector 18 21 23 11 44 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +€26m 5.0% 197 222 226 226 225 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026 +14% Sales (€m) 10.0% 19.5%9.3%8.9% EBITDA (€m) / margin Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 1) Special income of +€35m from the cancelation of a solar contract
Page 12
Net Debt at €261m after Siltronic and phased retirement effects1 Year-to-date development of net debt 12 -886 -261-34 -30 Net financial debt 31. Dec. 2025 569 Cash flow from operating activities Cash flow from investing before securities Dividend paid, WACKER Lease liabilities Fx, others Net financial debt 30. Sept 2026 119 0 Wacker Chemie AG, Q3 Earnings Call, 29 October 2026 1) Proceeds from sale of Siltronic shares +€355m in cash flow from investing, effect from changes to funding arrangement to phased retirement obligation +€120m in cash flow from operating activities
Page 13
Q&A
Page 14
Appendix Guidance FY 2026 updated 14 In €m FY 2025 Outlook 2026 Sales 5,485 Mid-single-digit percentage higher yoy EBITDA 427 In the upper half of the range from €625 to 750m (Prior: In the range from…) EBITDA margin (%) 7.8 Low-double-digit percentage figure Included in EBITDA / EBIT: restructuring expenses -103 0 Net cash flow -4 Positive, significantly1 higher than prior year CapEx 466 Approximately €300m Net debt 886 Approximately €200m (Prior: Approximately €500m) ROCE (%) -3.1 Positive, low-single-digit percentage figure 1) Significant: >10% Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 15
Appendix Q3 Results Year-over-year performance 15 In €m Q3 2026 Q3 2025 % Sales 1,466 1,340 9% EBITDA reported 217 112 94% EBITDA-margin 14.8% 8.3% - EBIT 103 -20 - EBIT-margin 7.0% -1.5% - Net income for the period 87 -82 - EPS 1.68 -1.73 - CapEx 71 111 -36% Net cash flow 476 19 >100% Net financial debt 261 1,156 -77% Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 16
Appendix Segment performance Q3 results for the group and by segment 16 In €m Q3 2026 Q3 2025 Sales EBITDA % Sales EBITDA % Chemicals 1,110 191 17.2 1,017 133 13.1 Silicones 729 116 16.0 673 86 12.8 Polymers 381 75 19.6 344 47 13.7 Biosolutions 100 8 7.9 93 8 8.8 Polysilicon 225 44 19.5 197 18 8.9 Others 36 -27 - 36 -47 - Consolidation -5 2 - -3 -1 - WACKER Group 1,466 217 14.8 1,340 112 8.3 Wacker Chemie AG, Q3 Earnings Call, 29 October 2026
Page 17
WACKER: Issuer, contact and additional information Publications 2025 ANNUAL REPORT & ESG DISCLOSURES Financial Calendar March 8, 2027 FY 2026 Results April 28, 2027 Q1 2027 Results May 5, 2027 AGM July 29, 2027 Q2 2027 Results October 28, 2027 Q3 2027 Results Joerg Hoffmann, CFA Tel. +49 89 6279 1633 | joerg.hoffmann@wacker.com Wacker Chemie AG Gisela-Stein-Straße 1, D-81671 Munich investor.relations@wacker.com Scott McCollister Tel. +49 89 6279 1560 | scott.mccollister@wacker.com Additional Information ISIN DE000WCH8881 WKN WCH888 Deutsche Börse WCH Investor relations contacts FACTBOOK FACTBOOK 17 Wacker Chemie AG, Q3 Earnings Call, 29 October 2026